SweetValueLab
Write for us

Agilent Technologies, Inc. — Intrinsic Value & Fair Price

A
NYSEHealthcareMedical - Diagnostics & ResearchCIK 0001090872agilent.comAbout A
Last close · Oct 16, 2026172.97−2.58 (−1.47%)
Market cap$48.8B
Model value · DCF · Perpetuity growth · 5y
79.20
Agilent Technologies closed at $172.97 — overvalued by 118% vs model.
54.60the model's range145.92

DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.

Other models
18.68 – 178.67
Wall St. target
180.00 4% below
Above model, 1y
20 of 20 days

Price and model value

Embed this card

A's close against its model value, as a 420×168 card for your own page. It updates nightly with this site and links back here.

Free to embed; keep the attribution link.
Loading chart…
What the marks mean
Daily close

Dividends

Quarterly · as of Oct 16, 2026
Yield, trailing 12 months
0.59%
Past 2 years
low 0.58%high 0.97%
Dividends per share, a year at a time
$0.78Oct ’21$0.84Oct ’22$0.90Oct ’23$0.94Oct ’24$0.99Sep ’25$1.02TTM
Dividends / free cash flow, FY2025
24.5%
Raised
13+ years in a row
Growth, 5 yrs
5.6% a year
Last change
+2.8% · Jan 2026
Every payment, with ex-dates · latest $0.255, paid Oct 28, 2026

Research on A

No posts on A yet.
Studied A from its filings? Guest posts are reviewed before they go live.Write about A →

How it is valued

Valued asMature & Stable
Low/slowing growth (~1% recent)Moderate margins (19% net margin)Highly cyclical earnings
What growth the price implies: the reverse DCF

Key figures

FY2025
P/E
37.8×
EV / EBITDA
27.4×
FCF yield
2.4%
Dividend yield, TTM
0.59%
Beta
1.21
Cost of capital (WACC)
9.47%
Full financials

Analyst actions

third-party, quoted
10-12Morgan Stanley · target190.00
10-07Barclays · target195.00
09-09UBS · target165.00
06-11Piper Sandler · “Neutral” from “Overweight”downgrade
Ratings, targets and estimates

The weekly

One email a week across every stock we cover: 13F filings, insider trades, earnings and new research. It covers the whole market, not just A. No account.

About Agilent Technologies

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

CEO
Padraig McDonnell
Headquarters
Santa Clara, CA
Employees
18,200
IPO
1999-11-18
Full company profile

Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; the formulas are in how we value a stock.